

Winreva[®] (sotatercept-csrk)
 Effective 10/1/2024

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Winreva[®] (sotatercept-csrk) is an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events.

Coverage Guidelines

Authorization may be granted for members new to the plan within the last 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. Member is 18 years of age or older
2. Member has a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1
3. Diagnosis of PAH was confirmed by ALL of the following:
 - a. Mean pulmonary arterial pressure (mPAP) > 20 mmHg
 - b. Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
 - c. Pulmonary vascular resistance (PVR) ≥ 3 Wood units
4. Member is either currently being treated with one agent from at least two of the following therapeutic classes OR there is a clinical rationale why treatment with the following therapeutic classes is not appropriate:
 - a. Endothelin receptor antagonists (e.g., bosentan, ambrisentan, macitentan)
 - b. Phosphodiesterase 5 inhibitors (e.g., tadalafil, sildenafil)
 - c. Soluble guanylate cyclase (sGC) stimulator (e.g., riociguat)

Continuation of Therapy

1. Prescriber submits documentation demonstrating the member has experienced a positive clinical response to therapy

Limitations

1. Initial and reauthorization requests will be approved for 12 months.

References

1. Bousseau S, Sobrano Fais R, Gu S, Frump A, Lahm T. Pathophysiology and new advances in pulmonary hypertension. *BMJ Med.* 2023;2(1):e000137. doi: 10.1136/bmjmed-2022-000137.
2. Food and Drug Administration (FDA). Winrevair integrated review. March 26, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761363Orig1s000IntegratedR.pdf. Accessed May 10, 2024.
3. Hadi DD, Marsool MDM, Marsool ADM, et al. Idiopathic pulmonary fibrosis: addressing the current and future therapeutic advances along with the role of sotatercept in the management of pulmonary hypertension. *Immun Inflamm Dis.* 2023;11(11):e1079. doi: 10.1002/iid3.1079.
4. Hassoun PM. Pulmonary arterial hypertension. *N Engl J Med.* 2021;385(25):2361-2376. doi:10.1056/NEJMra2000348.
5. Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. *N Engl J Med.* 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558.
6. Hoeper MM, Pausch C, Grunig E, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. *Eur Respir J.* 2022; 59(6): 2102024. doi: 10.1183/13993003.02024-2021.
7. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J.* 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237.
8. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. *N Engl J Med.* 2021;384(13):1204-1215. doi: 10.1056/NEJMoa2024277.
9. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. *Eur Respir J.* 2023;61(1):2201347. doi: 10.1183/13993003.01347-2022.
10. Hye T, Hossain MR, Saha D, Foyez, T, Ahsan F. emerging biologics for the treatment of pulmonary arterial hypertension. *J Drug Target.* 2023;31(5):1-15. doi:10.1080/1061186X.2023.2199351.
11. Institute for Clinical and Economic Review (ICER). Sotatercept for pulmonary arterial hypertension (final evidence report). January 8, 2024. https://icer.org/wp-content/uploads/2023/05/PAH_Final-Evidence-Report_For-Publication_01082024.pdf. Accessed May 8, 2024.
12. Jin Q, Chen D, Zhang X, et al. Medical management of pulmonary arterial hypertension: current approaches and investigational drugs. *Pharmaceutics.* 2023;15(6):1579. doi: 10.3390/pharmaceutics15061579.
13. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST Guideline and Expert Panel Report. *Chest.* 2019;155(3):565-586. doi: 10.1016/j.chest.2018.11.030.
14. Maron BA, Abman SH, Elliot CG, et al. Pulmonary arterial hypertension: diagnosis, treatment, and novel advances. *Am J Respir Crit Care Med.* 2021;203(12):14720-1487. doi: 10.1164/rccm.202012-43150.
15. Mathai SC, Puhon MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med.* 2012;186(5):428-433.
16. McLaughlin VV, Channick R, De Marco T, et al. Results of expert consensus on the treatment of pulmonary arterial hypertension with oral prostacyclin pathway agents. *Chest.* 2020;157(4):955-965.



17. Moutchia J, McClelland RL, Al-Naamani N, et al. Minimal clinically important difference in the 6-minute-walk distance for patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2023;207(8):1070-1079. doi: 10.1164/rccm.20208-1547OC.
18. Pulmonary Hypertension Association. About pulmonary hypertension. Pulmonary Hypertension Association Web site. Updated 2020. <https://phassociation.org/types-pulmonary-hypertension-groups/>. Accessed May 7, 2024.
19. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25 Suppl):D34-41.
20. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J*. 2019; 53(1): 1801913. doi: 10.1183/13993003.01913-2018.
21. Stringham R, Shah NR. Pulmonary arterial hypertension: an update on diagnosis and treatment. *Am Fam Physician*. 2010;82(4):370-7.
22. Vranka A, Diamanti E, Kularatne M, et al. Risk stratification in pulmonary arterial hypertension, update and perspectives. *J Clin Med*. 2023;12:4349. doi: 10.3390/jcm12134349.
23. Waxman AB, Systrom DM, Manimaran S, et al. SPECTRA Phase 2b study: impact of sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension. *Circ Heart Fail*. 2024 Apr 4:e011227. doi: 10.1161/CIRCHEARTFAILURE.123.011227. Online ahead of print.
24. Winrevair (sotatercept-csrk) [prescribing information]. Rahway, NJ: Merck Sharp & Dohme; March 2024.

Review History

08/14/2024 – Reviewed at August P&T. Effective 10/1/2024.

